Phase II Topical Immunomodulatory Therapy With Imiquimod for the Chemoprevention of Recurrent and High-Grade Cervical Intraepithelial Neoplasia (CIN).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Imiquimod (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 13 Jul 2016 Biomarkers information updated
- 10 Feb 2009 Actual end date (July 2004) added as reported by ClinicalTrials.gov.
- 10 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.